The company said the price was determined with consideration of the “clinical, societal, economic, and innovative value represented by this novel gene therapy.” Earlier last month, the Institute for Clinical and Economic Review, a Boston-based nonprofit research institute that estimates the value of drugs and other medical services, said Hemgenix would be fairly priced at upward of $2.9 million.
But Michael Gusmano, professor of health policy at Lehigh University and a research scholar at the Hastings Center, an independent bioethics research institute in Garrison, New York, says the price of Hemgenix and other gene therapies shouldn’t be considered a bargain. “It assumes that
→ Continue reading at Wired - Science